Treatment
Paclitaxel + Carboplatin clinical trials
We’re tracking 240 recruiting studies that include Paclitaxel + Carboplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT07023484RecruitingPhase 2
Timing of ovarian cancer surgery after chemo
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
GuangzhouAges 18 years+ - NCT07022535RecruitingPhase 2
Personalized timing of surgery for advanced ovarian cancer
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
Hong KongAges 18 years+ - NCT06977594Recruiting
Preventing allergic reactions during chemo for gynecologic cancer
This study tests a proactive approach to reduce allergic reactions to common chemotherapy drugs (paclitaxel and carboplatin) used for gynecologic cancers. It aims to make treatment safer and more comfortable for patients.
SeoulAges 19 years+ - NCT06927180RecruitingPhase 2
Study of SHR-A1811 plus pertuzumab before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
Zhengzhou, HenanAges 18–70 - NCT05173246RecruitingPhase 2
First-line treatment study for advanced small cell esophageal cancer
This Phase 2 trial tests JS001 plus TP as a first treatment for people with advanced or unresectable small cell esophageal cancer. It aims to see how well this combination controls the cancer and improves outcomes compared with starting treatment with standard options.
Guangzhou, GuangdongAges 18–75 - NCT06783647RecruitingPhase 2
LBL-024 combo for advanced solid tumors (NSCLC)
This trial tests a new drug combination for people with advanced non-small cell lung cancer or other solid tumors. It aims to see if adding LBL-024 to other treatments can help shrink tumors or slow their growth.
Hefei, AnhuiAges 18–75 - NCT06204614Enrolling by invitationEarly Phase 1
Drug screening for bladder cancer before surgery
This trial tests a tiny device placed into bladder tumors before surgery to see which drugs might work best for each patient, helping guide future treatment choices.
Boston, MassachusettsAges 18–120 - NCT05798819RecruitingPhase 3
PD-L1 cervical cancer trial with chemotherapy and possible bevacizumab
This Phase 3 study tests GLS-010 added to standard platinum chemotherapy, with or without bevacizumab, as a first treatment for cervical cancer that has persisted, come back, or spread. If you have PD-L1–positive tumors, the goal is to improve how long people can control the cancer compared with standard chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT04585490RecruitingPhase 3
Testing a personalized add-on treatment after stage III lung cancer
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
Stanford, CaliforniaAges 18 years+ - NCT07020065RecruitingPhase 2
Reduced chemo plus immunotherapy vs immunotherapy alone for older lung cancer patients
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
Fribourg, Villars-sur-GlâneAges 70 years+ - NCT04316364RecruitingPhase 3
New immunotherapy plus chemo for resectable lung cancer
This Phase 3 trial studies whether an immunotherapy drug (SHR-1316) added to standard chemotherapy helps people live longer or delay cancer returning after surgery. It focuses on people with resectable non-small cell lung cancer (NSCLC) that has not been treated before.
Beijing, Beijing MunicipalityAges 18–70 - NCT07505186RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for esophageal cancer
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
Hangzhou, ChinaAges 18–75 - NCT05737303RecruitingPhase 3
First-line chemotherapy comparison for advanced ovarian cancer
This Phase 3 trial compares two chemotherapy drug approaches (nab-paclitaxel vs another taxane drug) as the first treatment for advanced ovarian, fallopian tube, or peritoneal cancer. It aims to find which option works better and is tolerated better in people with stage III–IV disease.
Guangzhou, GuangdongAges 18–75 - NCT07317609RecruitingPhase 1
Immunotherapy plus chemo before endoscopic resection for esophageal cancer
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06942416RecruitingPhase 2
Study of iparomlimab and tuvonralimab with chemoradiation for recurrent cervical cancer
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
Jinan, Shandong RecruitingAges 18–75 - NCT07173751RecruitingPhase 3
Pumitamig for advanced triple-negative breast cancer
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
Springdale, ArkansasAges 18 years+ - NCT07057427RecruitingPhase 3
Nab-paclitaxel vs TCbHP for HER2-positive early breast cancer
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
Zhengzhou, HenanAges 18–70 - NCT07050043RecruitingPhase 3
Low-dose nivolumab plus chemo vs standard chemo for advanced lung cancer
This trial tests whether a lower dose of the immunotherapy drug nivolumab combined with standard chemotherapy works better than chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not been treated before.
Alor Star, KedahAges 18 years+ - NCT06292286Recruiting
Second surgery for recurrent ovarian cancer that responds to platinum
This trial tests whether having a second surgery after initial treatment can help people with ovarian cancer that came back but still responds to platinum-based chemotherapy. It may offer another option to remove remaining tumors and delay further treatments.
Hong KongAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT06474455RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for advanced solid tumors
This trial tests a new drug called SHR-9839 combined with other cancer treatments for people with advanced solid tumors, including a certain type of lung cancer. The goal is to see if the combination is safe and effective against the cancer.
Zhengzhou, HenanAges 18–75 - NCT02297217RecruitingPhase 2
Chemoradiation for advanced esophagus cancer that can’t be cured
This trial studies whether a combination of chemotherapy and radiation can help people with advanced esophageal cancer who cannot have curative treatment. It focuses on people who are having swallowing trouble and may be able to start treatment soon.
Calgary, AlbertaAges 18 years+
Common questions
- Are there clinical trials studying Paclitaxel + Carboplatin?
- Yes. Clin2 currently lists 240 recruiting studies that include Paclitaxel + Carboplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Paclitaxel + Carboplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Paclitaxel + Carboplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Paclitaxel + Carboplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.